Drugs / CRB-913
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07310901 | Dec 2025 → Jul 2026 overdue | — | Corbus Pharmaceuticals Inc. | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-12-11 | Corbus Pharmaceuticals Inc. | Results Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss corbuspharma.com ↗
A placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12) |
| 2025-06-30 | Corbus Pharmaceuticals Inc. | Results Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity corbuspharma.com ↗
An absence of treatment-related neuropsychiatric events was noted even at markedly higher doses than our modelling suggests would be required to achieve efficacy in clinical practice. |
| 2024-11-04 | Corbus Pharmaceuticals Inc. | Results Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 corbuspharma.com ↗
CRB-913 brain levels (both C max and AUC) were 15-fold lower than monlunabant at the same dose in mice. |
| 2023-10-17 | Corbus Pharmaceuticals Inc. | Results Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023 corbuspharma.com ↗ |
| 2022-09-22 | Corbus Pharmaceuticals Inc. | Results Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference corbuspharma.com ↗
The data show that in the diet-induced obesity (DIO) mouse model, CRB-913 monotherapy demonstrated a reduction in body weight, body fat content, food consumption, liver triglycerides, and liver fat deposits as well as improvements in insulin resistance and leptinemia. |
All press releases naming this drug 11 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRB-913 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07310901 ↗ |
| Action | Inhibit | “inverse agonist” NCT07310901 ↗ |
| Route | Oral | “They will receive CRB-913 in tablet form.” NCT07310901 ↗ |